Evommune (EVMN) Retained Earnings (2024 - 2026)

Evommune (EVMN) has reported Retained Earnings for 3 consecutive years, with -$242.8 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Retained Earnings changed N/A year-over-year to -$242.8 million; the TTM figure through Mar 2026 stood at -$242.8 million (changed N/A YoY), while the FY2025 annual figure was -$221.1 million, down 45.24% from the prior year.
• Retained Earnings declined to -$242.8 million in Q1 2026 per EVMN's latest filing, from -$221.1 million in the prior quarter.
• Across five years, Retained Earnings topped out at -$152.2 million in Q4 2024 and bottomed at -$242.8 million in Q1 2026.
• Historically, Retained Earnings has averaged -$202.2 million across 3 years, with a median of -$206.9 million in 2025.
• On a YoY basis, Retained Earnings climbed as much as 45.24% in 2025 and fell as far as 45.24% in 2025.
• Evommune's Retained Earnings stood at -$152.2 million in 2024, then sank by 45.24% to -$221.1 million in 2025, then decreased by 9.8% to -$242.8 million in 2026.
• Business Quant data shows EVMN's Retained Earnings at -$242.8 million in Q1 2026, -$221.1 million in Q4 2025, and -$192.8 million in Q3 2025.